在肿瘤和/或血浆样本中报道的不依赖EGFR耐药机制包括MET扩增[39-41]、HER-2[39, 42]和FGFR[43]、MAPK激活[43]、KRAS突变、PI3KCA[35]、BRAF[44]、PTEN缺失[36]和向小细胞肺癌(small cell lung cancer, SCLC)转化[45]。此外,SFK/FAK信号也可通过维持AKT和MAPK通路减弱奥希替尼在耐药模型中的疗效[46]。. The gene discussed is PTK2; the disease is small cell lung carcinoma.